Stéphane Collaud1, Christian Benden2, Christoph Ganter3, Sven Hillinger1, Isabelle Opitz1, Didier Schneiter1, Reto Schuepbach4, Ilhan Inci1, Walter Weder5. 1. Division of Thoracic Surgery, University Hospital of Zurich, Zurich, Switzerland. 2. Division of Pulmonary Medicine, University Hospital of Zurich, Zurich, Switzerland. 3. Division of Medical Intensive Care Unit, University Hospital of Zurich, Zurich, Switzerland. 4. Division of Surgical Intensive Care Unit, University Hospital of Zurich, Zurich, Switzerland. 5. Division of Thoracic Surgery, University Hospital of Zurich, Zurich, Switzerland. Electronic address: walter.weder@usz.ch.
Abstract
BACKGROUND: Extracorporeal life support (ECLS) as a bridge to lung retransplantation has been reported only anecdotally. Thus, we analyzed combined data from our center with pooled data from published studies to identify selection criteria for this advanced therapy. METHODS: Four patients at our center were bridged on ECLS to lung retransplantation. Patient data were retrospectively retrieved from electronic records. The MEDLINE database was searched using the PubMed engine and yielded 13 relevant studies that included a minimum of 3 patients bridged to lung retransplantation, and four studies described detailed data on 17 patients. Patient data from our center (n = 4) were pooled with data from the MEDLINE database (n = 17) and analyzed. RESULTS: Of 21 patients, 3 (14%) died on ECLS awaiting retransplantation, and 18 (86%) underwent retransplantation after a median of 37 months (range, 0 to 168 months) after primary transplantation. Type of ECLS was extracorporeal carbon dioxide removal (ECCO2R) in 4, venovenous extracorporeal membrane oxygenation (ECMO) in 7, venoarterial ECMO in 5, or was not mentioned in 2. The 90-day postoperative mortality was 28%. Overall 1-year survival was 48%. Patients bridged to retransplantation with ECCO2R/venovenous ECMO (p = 0.05) or on awake ECMO (p = 0.06) showed strong trends toward better survival in univariate analysis. Univariate and multivariate analysis identified a longer intertransplant interval as a statistically significant favorable prognostic factor. In a selected subgroup of patients (awake ECCO2R/venovenous ECMO support and intertransplant interval >2 years), 1-year survival reached 67%. CONCLUSIONS: Despite limited overall 1-year survival for patients bridged with ECLS to lung retransplantation, careful patient selection may yield an acceptable 1-year survival of 67%.
BACKGROUND: Extracorporeal life support (ECLS) as a bridge to lung retransplantation has been reported only anecdotally. Thus, we analyzed combined data from our center with pooled data from published studies to identify selection criteria for this advanced therapy. METHODS: Four patients at our center were bridged on ECLS to lung retransplantation. Patient data were retrospectively retrieved from electronic records. The MEDLINE database was searched using the PubMed engine and yielded 13 relevant studies that included a minimum of 3 patients bridged to lung retransplantation, and four studies described detailed data on 17 patients. Patient data from our center (n = 4) were pooled with data from the MEDLINE database (n = 17) and analyzed. RESULTS: Of 21 patients, 3 (14%) died on ECLS awaiting retransplantation, and 18 (86%) underwent retransplantation after a median of 37 months (range, 0 to 168 months) after primary transplantation. Type of ECLS was extracorporeal carbon dioxide removal (ECCO2R) in 4, venovenous extracorporeal membrane oxygenation (ECMO) in 7, venoarterial ECMO in 5, or was not mentioned in 2. The 90-day postoperative mortality was 28%. Overall 1-year survival was 48%. Patients bridged to retransplantation with ECCO2R/venovenous ECMO (p = 0.05) or on awake ECMO (p = 0.06) showed strong trends toward better survival in univariate analysis. Univariate and multivariate analysis identified a longer intertransplant interval as a statistically significant favorable prognostic factor. In a selected subgroup of patients (awake ECCO2R/venovenous ECMO support and intertransplant interval >2 years), 1-year survival reached 67%. CONCLUSIONS: Despite limited overall 1-year survival for patients bridged with ECLS to lung retransplantation, careful patient selection may yield an acceptable 1-year survival of 67%.
Authors: Andrea Morelli; Lorenzo Del Sorbo; Antonio Pesenti; V Marco Ranieri; Eddy Fan Journal: Intensive Care Med Date: 2017-01-28 Impact factor: 17.440
Authors: Jeremiah William Awori Hayanga; Heather K Hayanga; James H Fugett; Kelsey A Musgrove; Ghulam Abbas; Christopher R Ensor; Vinay Badhwar; Norihisa Shigemura Journal: Transpl Int Date: 2020-05-12 Impact factor: 3.782
Authors: Raphaël Giraud; Carlo Banfi; Benjamin Assouline; Amandine De Charrière; Maurizio Cecconi; Karim Bendjelid Journal: Ann Intensive Care Date: 2021-03-11 Impact factor: 6.925